Format

Send to

Choose Destination
Transplantation. 2019 Nov;103(11):2373-2382. doi: 10.1097/TP.0000000000002599.

Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes.

Author information

1
Division of Nephrology, Washington University School of Medicine, St. Louis, MO.
2
Division of Nephrology, Saint Louis University School of Medicine, St. Louis, MO.
3
Division of Nephrology, University of Alberta, Edmonton, AB, Canada.
4
Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MI.
5
Center for Abdominal Transplantation, Saint Louis University, St. Louis, MO.
6
Division of Transplantation, Department of Surgery, Lahey Clinic, Burlington, MA.
7
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.
8
Center for Transplantation, Johns Hopkins School of Medicine, Baltimore, MD.
9
School of Pharmacy, Southern Illinois University, Edwardsville, MO.
10
Hennepin County Medical Center, Minneapolis, MN.

Abstract

BACKGROUND:

Cannabis is categorized as an illicit drug in most US states, but legalization for medical indications is increasing. Policies and guidance on cannabis use in transplant patients remain controversial.

METHODS:

We examined a database linking national kidney transplant records (n = 52 689) with Medicare claims to identify diagnoses of cannabis dependence or abuse (CDOA) and associations [adjusted hazard ratio (aHR) with 95% upper and lower confidence limits (CLs)] with graft, patient, and other clinical outcomes.

RESULTS:

CDOA was diagnosed in only 0.5% (n = 254) and 0.3% (n = 163) of kidney transplant recipients in the years before and after transplant, respectively. Patients with pretransplant CDOA were more likely to be 19 to 30 years of age and of black race, and less likely to be obese, college-educated, and employed. After multivariate and propensity adjustment, CDOA in the year before transplant was not associated with death or graft failure in the year after transplant, but was associated with posttransplant psychosocial problems such as alcohol abuse, other drug abuse, noncompliance, schizophrenia, and depression. Furthermore, CDOA in the first year posttransplant was associated with an approximately 2-fold increased risk of death-censored graft failure (aHR, 2.29; 95% CL, 1.59-3.32), all-cause graft loss (aHR, 2.09; 95% CL, 1.50-2.91), and death (aHR, 1.79; 95% CL, 1.06-3.04) in the subsequent 2 years. Posttransplant CDOA was also associated with cardiovascular, pulmonary, and psychosocial problems, and with events such as accidents and fractures.

CONCLUSIONS:

Although associations likely, in part, reflect associated conditions or behaviors, clinical diagnosis of CDOA in the year after transplant appears to have prognostic implications for allograft and patient outcomes. Recipients with posttransplant CDOA warrant focused monitoring and support.

PMID:
30747847
PMCID:
PMC6679817
[Available on 2020-11-01]
DOI:
10.1097/TP.0000000000002599

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center